Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Compare

1,026 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ADPT Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Adaptive

Biotechnologies

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ADPT Stock 12 Month Forecast

Average Price Target

$20.86

▲(30.05% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Adaptive Biotechnologies in the last 3 months. The average price target is $20.86 with a high forecast of $22.00 and a low forecast of $20.00. The average price target represents a 30.05% change from the last price of $16.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","23":"$23","10.25":"$10.25","14.5":"$14.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,10.25,14.5,18.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.39,18.66769230769231,18.945384615384615,19.223076923076924,19.50076923076923,19.77846153846154,20.056153846153848,20.333846153846153,20.611538461538462,20.88923076923077,21.166923076923077,21.444615384615386,21.72230769230769,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.39,18.580000000000002,18.77,18.96,19.15,19.34,19.53,19.72,19.91,20.1,20.29,20.48,20.669999999999998,{"y":20.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.39,18.513846153846153,18.63769230769231,18.76153846153846,18.885384615384616,19.00923076923077,19.133076923076924,19.256923076923076,19.380769230769232,19.504615384615384,19.62846153846154,19.752307692307692,19.876153846153848,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.36,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.39,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$20.86

Lowest Price Target$20.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Brackmann

William Blair

Buy

―

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT) and Medpace Holdings (NASDAQ: MEDP)

Kallum Titchmarsh

Morgan Stanley

$21

Hold

30.92%

Upside

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN), RegenXBio (NASDAQ: RGNX) and Adaptive Biotechnologies (NASDAQ: ADPT)

David Westenberg

Piper Sandler

$20

Buy

24.69%

Upside

Reiterated

02/09/26

Piper Sandler Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)

William Bonello

Craig-Hallum

$20

Buy

24.69%

Upside

Assigned

02/06/26

Analysts Are Bullish on These Healthcare Stocks: Adaptive Biotechnologies (ADPT), Opus Genetics (IRD)

Sebastian Sandler

J.P. Morgan

$20→$21

Buy

30.92%

Upside

Reiterated

02/06/26

Adaptive Biotechnologies price target raised to $21 from $20 at JPMorganAdaptive Biotechnologies price target raised to $21 from $20 at JPMorgan

Mark Massaro

BTIG

$21→$22

Buy

37.16%

Upside

Reiterated

02/06/26

Adaptive Biotechnologies: Sustained MRD Growth, Pricing Power, and Strategic Positioning Support Buy Rating and Premium Valuation

Daniel Brennan

TD Cowen

$20→$21

Buy

30.92%

Upside

Reiterated

02/05/26

Adaptive Biotechnologies: Strong MRD Momentum, Enhanced 2026 Outlook, and Clear Path to Profitability Support Buy Rating

Subbu Nambi

Guggenheim

$20→$21

Buy

30.92%

Upside

Reiterated

01/26/26

Adaptive Biotechnologies price target raised to $21 from $20 at GuggenheimAdaptive Biotechnologies price target raised to $21 from $20 at Guggenheim

Sung Ji Nam

Scotiabank

$12

Buy

-25.19%

Downside

Reiterated

05/05/25

Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)

Matthew Sykes

Goldman Sachs

$8→$9

Buy

-43.89%

Downside

Upgraded

03/21/25

Adaptive Biotechnologies (ADPT) was upgraded to a Buy Rating at Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Brackmann

William Blair

Buy

―

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT) and Medpace Holdings (NASDAQ: MEDP)

Kallum Titchmarsh

Morgan Stanley

$21

Hold

30.92%

Upside

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN), RegenXBio (NASDAQ: RGNX) and Adaptive Biotechnologies (NASDAQ: ADPT)

David Westenberg

Piper Sandler

$20

Buy

24.69%

Upside

Reiterated

02/09/26

Piper Sandler Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)

William Bonello

Craig-Hallum

$20

Buy

24.69%

Upside

Assigned

02/06/26

Analysts Are Bullish on These Healthcare Stocks: Adaptive Biotechnologies (ADPT), Opus Genetics (IRD)

Sebastian Sandler

J.P. Morgan

$20→$21

Buy

30.92%

Upside

Reiterated

02/06/26

Adaptive Biotechnologies price target raised to $21 from $20 at JPMorganAdaptive Biotechnologies price target raised to $21 from $20 at JPMorgan

Mark Massaro

BTIG

$21→$22

Buy

37.16%

Upside

Reiterated

02/06/26

Adaptive Biotechnologies: Sustained MRD Growth, Pricing Power, and Strategic Positioning Support Buy Rating and Premium Valuation

Daniel Brennan

TD Cowen

$20→$21

Buy

30.92%

Upside

Reiterated

02/05/26

Adaptive Biotechnologies: Strong MRD Momentum, Enhanced 2026 Outlook, and Clear Path to Profitability Support Buy Rating

Subbu Nambi

Guggenheim

$20→$21

Buy

30.92%

Upside

Reiterated

01/26/26

Adaptive Biotechnologies price target raised to $21 from $20 at GuggenheimAdaptive Biotechnologies price target raised to $21 from $20 at Guggenheim

Sung Ji Nam

Scotiabank

$12

Buy

-25.19%

Downside

Reiterated

05/05/25

Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)

Matthew Sykes

Goldman Sachs

$8→$9

Buy

-43.89%

Downside

Upgraded

03/21/25

Adaptive Biotechnologies (ADPT) was upgraded to a Buy Rating at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Adaptive Biotechnologies

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+11.99%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +11.99% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

11/14 ratings generated profit

Average Return

+62.45%

reiterated a buy rating 15 days ago

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +62.45% per trade.

2 Years

xxx

Success Rate

11/14 ratings generated profit

Average Return

+126.72%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +126.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ADPT Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ADPT has received 20 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. ADPT average Analyst price target in the past 3 months is 20.86.

Each month's total comprises the sum of three months' worth of ratings.

ADPT Financial Forecast

ADPT Earnings Forecast

Next quarter’s earnings estimate for ADPT is -$0.16 with a range of -$0.20 to -$0.14. The previous quarter’s EPS was -$0.09. ADPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ADPT has Performed in-line its overall industry.

ADPT Sales Forecast

Next quarter’s sales forecast for ADPT is $60.70M with a range of $55.19M to $64.00M. The previous quarter’s sales results were $71.68M. ADPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ADPT has Performed in-line its overall industry.

ADPT Stock Forecast FAQ

What is ADPT’s average 12-month price target, according to analysts?

Based on analyst ratings, Adaptive Biotechnologies Corp’s 12-month average price target is 20.86.

What is ADPT’s upside potential, based on the analysts’ average price target?

Adaptive Biotechnologies Corp has 30.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ADPT a Buy, Sell or Hold?

Adaptive Biotechnologies Corp has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Adaptive Biotechnologies Corp’s price target?

The average price target for Adaptive Biotechnologies Corp is 20.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $20.00. The average price target represents 30.05% Increase from the current price of $16.04.

What do analysts say about Adaptive Biotechnologies Corp?

Adaptive Biotechnologies Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ADPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

ADPT Analyst Ratings

ADPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Adaptive Biotechnologies

ADPT Analyst Recommendation Trends

ADPT Financial Forecast

ADPT Earnings Forecast

ADPT Sales Forecast

ADPT Stock Forecast FAQ

Detailed List of Analyst Forecasts